Revolution Medicines, Inc.
$139.48
$4.64(-3.22%)
Revolution Medicines, Inc.
RVMD
$139.48
$4.64(-3.22%)
Revolution Medicines, Inc.
RVMD
NASDAQ
$139.48
$4.64(-3.22%)
Chart
Upcoming Earnings
Next report date
May 6, 2026
Report period
Q2 2026
EPS Estimate
$-1.83
Revenue Estimate
$2.43M
Key stats
52-Week Range$139.48
$34.00
$155.70
Market capitalization
$31.30BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
-23.44Basic EPS (TTM)
$-5.95Net income (TTM)
$-1.13BRevenue (TTM)
$0.00Avg. volume
2.88MBeta (1Y)
1.01Employees
616Market capitalization
$31.30BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
-23.44Basic EPS (TTM)
$-5.95Net income (TTM)
$-1.13BRevenue (TTM)
$0.00Avg. volume
2.88MBeta (1Y)
1.01Employees
616Screener Quick Check
Sign in to check this stock against your screeners
Sign InAbout Revolution Medicines, Inc.
Sector
Healthcare
Industry
Biotechnology
CEO
Mark A. Goldsmith
Website
www.revmed.comHeadquarters
700 Saginaw Drive, Redwood City, CA, 94063
IPO Date
2020-02-13
Identifiers
ISIN
US76155X1000Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets...
Related Stocks
$28.32
1D:
-0.1%
1Y:
144.8%
BMG762791017Healthcare
Mkt Cap
$20.27B
P/E Ratio TTM
-24.0
Revenue TTM
$13.31M
Beta
1.21
Earnings TTM
$-809.24M
Dividend Yield TTM
0.00%
$46.71
1D:
-1.2%
1Y:
67.8%
US60770K1079Healthcare
Mkt Cap
$18.52B
P/E Ratio TTM
-5.6
Revenue TTM
$1.94B
Beta
1.06
Earnings TTM
$-2.82B
Dividend Yield TTM
0.00%
Dividend Overview
This company does not pay dividends
Financials
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate